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Background: In Parkinson’s disease (PD), the effects of dopaminergic medication on 
straight walking and turning were mainly investigated under single tasking (ST) condi-
tions. However, multitasking situations are considered more daily relevant.
Methods: Thirty-nine early-to-moderate PD patients performed the following standard-
ized ST and dual tasks as fast as possible for 1 min during On- and Off-medication while 
wearing inertial sensors: straight walking and turning, checking boxes, and subtracting 
serial 7s. Quantitative gait parameters as well as velocity of the secondary tasks were 
analyzed.
results: The following parameters improved significantly in On-medication during ST: 
gait velocity during straight walking (p =  0.03); step duration (p =  0.048) and peak 
velocity (p = 0.04) during turning; velocity of checking boxes during ST (p = 0.04) and 
DT (p = 0.04). Velocity of checking boxes was the only parameter that also improved 
during DT.
conclusion: These results suggest that dopaminergic medication does not relevantly 
influence straight walking and turning in early-to-moderate PD during DT.
Keywords: Parkinson’s disease, dual tasking, gait, turning, wearable sensors
inTrODUcTiOn
Parkinson’s disease (PD) affects a variety of gait parameters and cognitive functions, such as atten-
tion, visuospatial perception, and executive functions (Blin et al., 1991; Dubois and Pillon, 1996; 
O’Sullivan et al., 1998; Muslimovic et al., 2005). These latter parameters have repeatedly been shown 
to influence quality of gait (Yogev-Seligmann et al., 2008; Smulders et al., 2013) and may, in particu-
lar, influence the quality of turning phases (Stack et al., 2004; McNeely and Earhart, 2011; Song et al., 
2012). Due to how neurodegenerative diseases affect daily life activities, turning becomes a frequent 
and crucial activity that is associated with falls (Bloem et al., 2001; Stack et al., 2004).
TaBle 1 | Demographic data of 39 PD patients in On- and Off-medication 
conditions.
Off-medication On-medication p-Value
Age (years) 65.2 (6.9)
Gender M:31; F:8
MMSE (0–30) 29 (2)
BDI (0–63) 7 (6)
UPDRS III (0–132) 30 (9) 21 (7) <0.0001
Hoehn and Yahr (1–5) 35 patients stage 2
4 patients stage 3
BDI, Beck Depression Inventory; MMSE, Mini Mental State Examination; UPDRS III, 
motor part of the Unified Parkinson’s Disease Rating Scale.
January 2016 | Volume 8 | Article 42
Elshehabi et al. Medication Effect on DT in PD Patients
Frontiers in Aging Neuroscience | www.frontiersin.org
Dopaminergic medication has a significant effect on many 
PD symptoms, with the most relevant improvements found for 
distal symptoms (Lees et  al., 2009). Although not as effective, 
dopaminergic medication also influences PD-specific straight 
walking (Blin et al., 1991; Lord et al., 2011; McNeely et al., 2012) 
and some turning deficits (McNeely and Earhart, 2011). These 
studies mainly used single tasking (ST) paradigms, which may fall 
short due to multiple reasons. First, gait is a complex task, involv-
ing cognitive elements (Maetzler et al., 2013) Second, dopamin-
ergic medication also influences cognitive functions. Improving 
some of them yet deteriorating others (Cools et al., 2001, 2003). 
Finally, ST walking is rarely or never performed during every day 
situations, since multitasking is performed during virtually all 
aspects of daily life activities, including walking phases (O’Shea 
et  al., 2002; Hausdorff et  al., 2003). Therefore, the influence of 
dopaminergic medication on straight walking and turning in PD 
should not only be assessed under ST but also under standardized 
multitasking situations.
In this study, we focused on the effect of dopaminergic medi-




Forty-four PD patients with a Hoehn and Yahr (1967) score 
between 2 and 3 and a Mini Mental State Examination score >24 
(Folstein et al., 1975) were recruited from the ward and the out-
patient clinic of the Neurology department, University Hospital 
Tuebingen. Diagnosis of PD was based on the UK Brain Bank 
Society criteria (Gibb and Lees, 1988). We included only individu-
als affected by a mild-to-moderate stage, as these patients have 
only subtle “subclinical” gait disturbances (Mirelman et al., 2011; 
Hass et al., 2012) and therefore may be those who benefit most 
effectively from potential treatment or even preventive options. 
The response to dopaminergic therapy was evaluated using the 
motor part of the revised version of the Unified Parkinson’s Disease 
Rating Scale (UPDRS III) (Goetz et  al., 2008) during On- and 
Off-medication. Off-medication was defined as withdrawal from 
dopaminergic medication overnight. On-medication condition 
was defined as 30 min to 2 h after the intake of the participant’s 
usual dose of dopaminergic medication, considering each study 
participant’s perception of having a “Good On Phase.” The ethical 
committee of the medical faculty of the University of Tuebingen 
approved the study (Nr 715/2011BO2) and all participants pro-
vided a written informed consent.
Tasks
For the assessment of ST straight walking and turning, participants 
walked as fast as possible up and down a 20-m distance in an at 
least 2 m wide hallway for 1 min (Mancini, 2011). ST checking 
boxes and serial subtracting 7s tasks were performed also as fast 
as possible while standing (crossing 32 empty boxes on a sheet of 
paper; subtracting a series of ten consecutive steps of 7) (Bock, 
2008; Hobert et al., 2011). For the DT assessment, study partici-
pants performed the checking boxes and the subtracting serial 7s 
tasks also for 1 min, respectively, in parallel with the walking task 
(Brauer and Morris, 2010). For the DT assessments, participants 
were instructed to perform both tasks as fast as possible.
Movement assessment
All participants wore an unobtrusive movement analysis system 
(Mobility Lab®, APDM, OR, USA) (Mancini, 2011) during the 
tasks. For the analysis presented here, data from the feet and 
waist sensors were used. For determination of the velocity of the 
secondary tasks, a stopwatch was used.
Data analysis
Based on the previous literature (Plotnik et al., 2007; Lord et al., 
2011; Galna et  al., 2013), we selected the following six gait 
parameters to assess the quality of the straight walking phase: 
gait velocity, step frequency, double limb support time, stride 
length asymmetry, stride duration variability, and double limb 
support variability. These parameters represent different domains 
of walking (pace, variability, and postural control) and have 
been shown to be relatively independent from each other (Lord 
et al., 2013). Stride duration variability and double limb support 
variability were calculated using the SD of the first 30 steps of the 
straight walk, as previous work (Galna et al., 2013) has shown the 
reliability of this approach. From the turning phase, we assessed 
total duration, step duration, number of steps, peak velocity, and 
the last step duration (Salarian et  al., 2009; Hong and Earhart, 
2010). Parameters were extracted and organized using Matlab 
8.4. On- and Off-medication conditions were compared with 
paired t-test. JMP 11.1.1 statistical software was used. Based on 
the exploratory character of the study, uncorrected p < 0.05 was 
considered significant.
resUlTs
From the 44 patients included in this study, 5 showed changes in 
the UPDRS III scores between 0 and 2 points, which was con-
sidered clinically not meaningful (Schrag et al., 2006; Shulman 
et al., 2010) and led to the exclusion of these patients from further 
analysis. The remaining 39 PD patients showed an improvement 
in the score of ≥5 points during On- compared to Off-medication, 
which was considered clinically significant (Schrag et al., 2006; 
Shulman et al., 2010). Detailed demographic and clinical data are 
presented in Table 1.
FigUre 1 | significant differences of gait parameters between On- and Off-medication were only observed under single tasking conditions, and 
affected (1) gait velocity, (2) turning peak velocity, and (3) turning step duration. Checking boxes velocity was the only parameter significantly affected by 
medication during single (4) and dual tasking (5). The mean differences for each patient (black dots), as well as mean values (full lines) and SEs (dotted lines) of the 
cohort are indicated, showing that differences between medication statuses (y axes) were not relevantly dependent on the absolute values of the respective 
parameters (x axes).
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effect of Medication on gait and Turning 
Parameters during sT and DT
During ST straight walking, PD patients had significantly higher 
gait velocity in On- than in Off-medication condition (p = 0.03) 
(Figure 1). Other gait parameters showed no significant differ-
ence between the On- and Off-medication conditions. During 
the ST turning phases, study participants showed significantly 
lower step duration and higher peak velocity of turning in 
On- compared to Off-medication condition (p  =  0.048 and 
0.04, respectively) (Figure  1). The rest of the turning param-
eters showed no significant changes in On- compared to Off-
medication conditions.
During both checking boxes and serial subtraction DT set-
tings, no straight walking and turning parameter changed sig-
nificantly between On- and Off-medication conditions. Details 
are provided in Table 2.
effect of Medication on secondary 
cognitive Tasks during sT and DT
For the checking boxes task, the velocity increased significantly 
during On-medication condition in ST (p = 0.04) as well as dur-
ing DT (p = 0.04) compared to Off-medication.
In regard to the serial subtraction test, there was no difference 
in the velocity of performing the task during ST (p = 0.51) or DT 
(p = 0.85) between the On- and Off-medication conditions. For 
details see Table 2.
DiscUssiOn
The main result of this study with PD patients – including novel 
aspects such as assessment under challenging conditions, new 
DT paradigms, inclusion of DT assessment during turns, and 
analysis of a specific set of quantitative gait parameters – is that 
dopaminergic medication-induced changes of gait, which are 
detectable under ST conditions, are not observable under more 
daily relevant (Silsupadol et al., 2006; Hackney and Earhart, 2010) 
DT conditions.
In line with previous studies (Baltadjieva et al., 2006; Hong and 
Earhart, 2010; Lord et al., 2011; Galna et al., 2015), dopaminergic 
medication improved gait velocity during straight walking under 
ST conditions. This improvement can certainly have advantages; 
for example, it makes affected patients able to move faster from 
one place to another. However, the disadvantage is that other gait 
parameters obviously do not improve comparably; in fact, none 
TaBle 2 | Performances of straight walking, turning, and secondary 
cognitive tasks in sT and DT conditions.
Parameter Off-medication On-medication p-Value
straight walking (sT)
Gait velocity (m/s) 1.58 (0.16) 1.61 (0.16) 0.03
Step frequency (step/min) 128 (9) 129 (13) 0.25
Double limb support time (%) 16.3 (4.3) 16.2 (4.6) 0.78
Stride length asymmetry (%) 1.60 (0.54) 1.50 (0.53) 0.26
Stride duration variability (SDa) 0.03 (0.01) 0.03 (0.01) 0.78
Double limb support variability 
(SD)
2.2 (0.7) 2.4 (1.0) 0.27
straight walking during checking boxes (DT)
Gait velocity (m/s) 1.37 (0.17) 1.35 (0.19) 0.18
Step frequency (step/min) 117 (11) 118 (13) 0.49
Double limb support time (%) 19.7 (4.5) 19.4 (4.9) 0.56
Stride length asymmetry (%) 1.87 (0.60) 1.79 (0.66) 0.35
Stride duration variability (SDa) 0.04 (0.02) 0.04 (0.02) 0.76
Double limb support variability 
(SD)
2.8 (1.2) 2.5 (1.1) 0.22
straight walking during serial subtraction (DT)
Gait velocity (m/s) 1.35 (0.21) 1.37 (0.18) 0.27
Step frequency (step/min) 115 (11) 115 (11) 0.96
Double limb support time (%) 19.1 (4.6) 19.7 (4.2) 0.77
Stride length asymmetry (%) 1.64 (0.59) 1.55 (0.56) 0.34
Stride duration variability (SDa) 0.04 (0.03) 0.04 (0.04) 0.90
Double limb support variability 
(SD)
2.3 (1.6) 2.3 (1.4) 0.69
Turning (sT)
Total duration (s) 2.4 (1.1) 2.2 (0.5) 0.18
Step duration (s) 0.53 (0.05) 0.51 (0.05) 0.048
Number of steps (/turn) 5.5 (1.1) 5.3 (1.0) 0.23
Peak velocity (°/s) 164 (34) 173 (37) 0.04
Last step duration (s) 0.48 (0.04) 0.48 (0.04) 0.18
Turning during checking boxes (DT)
Total duration (s) 3.3 (1.0) 3.7 (1.5) 0.68
Step duration (s) 0.66 (0.32) 0.63 (0.19) 0.30
Number of steps (/turn) 6.5 (1.6) 6.6 (1.9) 0.90
Peak velocity (°/s) 130 (32) 129 (35) 0.84
Last step duration (s) 0.53 (0.06) 0.53 (0.05) 0.49
Turning during serial subtraction (DT)
Total duration (s) 2.8 (1.1) 2.7 (0.9) 0.41
Step duration (s) 0.60 (0.09) 0.62 (0.20) 0.41
Number of steps (/turn) 5.8 (1.8) 5.4 (1.2) 0.09
Peak velocity (°/s) 147 (42) 154 (40) 0.31
Last step duration (s) 0.53 (0.06) 0.54 (0.08) 0.63
secondary tasks
Number of checked boxes ST 
(/min)
89 (16) 98 (16) 0.04
Number of checked boxes DT 
(/min)
60 (16) 65 (14) 0.04
Number of serial subtractions 
ST (/min)
27 (16) 31 (18) 0.51
Number of serial subtractions 
DT (/min)
21 (11) 22 (11) 0.85
Values are presented with mean and SD. The paired t-test was used for statistical 
analysis.
aSD, standard deviation of the first 30 steps from straight walking.
ST, single tasking, DT, dual tasking.
The numbers in bold show the significant p-values.
January 2016 | Volume 8 | Article 44
Elshehabi et al. Medication Effect on DT in PD Patients
Frontiers in Aging Neuroscience | www.frontiersin.org
of the other qualitative gait parameters tested in this study was 
significantly influenced by dopaminergic medication during ST 
straight walking. This widening gap between faster gait veloc-
ity and lack of improvement of variability and postural control 
associated gait parameters during ST straight walking under 
dopaminergic On- compared to Off-medication may increase 
dynamic balance deficits and risk of falling (Boonstra et  al., 
2008). These findings are in agreement with results described 
in previous studies. For example, others found that dopamin-
ergic medication does not have a relevant effect on stride time 
variability (Hausdorff et al., 2003; Lord et al., 2011). Stride time 
variability has been shown to be associated with attention and 
cognitive abilities and deteriorates during the course of the dis-
ease (Hausdorff et al., 2003; Lord et al., 2011). We also confirmed 
previous results (Schaafsma et  al., 2003; Almeida et  al., 2007) 
where step frequency and double limb support variability were 
not relevantly influenced by dopaminergic medication during 
ST straight walking. Therefore, although these latter parameters 
are obviously affected by PD (Schaafsma et  al., 2003; Almeida 
et  al., 2007), the pathological correlate is most probably not 
of dopaminergic origin. This observation is supported by the 
results from studies addressing mechanisms of gait impairments 
in PD patients and how beneficial the medication is to improve 
them (Blin et al., 1991; Schaafsma et al., 2003; Baker et al., 2008; 
Rochester et al., 2011, 2012).
Contrary to our results, another study investigating a similar 
research question (Rochester et al., 2011) detected a significant 
improvement of gait variability under On-medication. This dif-
ference may be best explained by the differences of the designs 
and protocols used. While the previous study assessed PD 
patients under convenient speed conditions, we measured under 
as fast as possible conditions. Based on recent literature, we argue 
that subtle symptoms, as they are already present in mild-to-
moderate PD (Hass et  al., 2012), may be detected with higher 
sensitivity when using challenging conditions (Mirelman et al., 
2011; Maetzler et al., 2013; Bergareche et al., 2015).
The influence of dopaminergic medication on ST gait may be 
higher during turning periods than during straight walking. In 
agreement with a previous study (McNeely and Earhart, 2011), 
dopaminergic medication had a significant positive effect on two 
parameters related to the velocity of turning, i.e., step duration and 
peak turning velocity. Therefore, comparably to previous studies 
(Hong and Earhart, 2010; McNeely et al., 2012; Song et al., 2012; 
Curtze et al., 2015) and also with the results obtained from the 
ST straight walking assessment, dopaminergic treatment seems 
to improve the velocity-dependent parameters significantly, but 
not those parameters that indicate control and timing of turning. 
Therefore, the main conclusion from the straight walking results 
may also hold true for ST turning: the widening gap between pace 
and, e.g., variability measures under dopaminergic On- compared 
to Off-medication, could be considered negative for the safety of 
the task. However, studies investigating the effect of medication on 
turning in PD are scarce and provide conflicting results (Hong and 
Earhart, 2010; McNeely and Earhart, 2011; McNeely et al., 2012; 
Curtze et al., 2015). Furthermore, to the best of our knowledge, 
this study is the first to investigate turning during DT conditions. 
Eventually, future studies are necessary, considering actually 
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available information and including different turning conditions, 
to clarify these differences among existing studies conclusively.
As mentioned above, the significant gait differences found 
during ST were not observed during DT. This finding was not 
influenced by the nature of the secondary task. As we may per-
form DT during many of our normal waking state phases, our 
results suggest a negligible effect of dopaminergic medication 
on a relevant proportion of walking during everyday situations. 
If confirmed in future studies, this finding should motivate the 
development of supportive treatment strategies for PD-associated 
gait deficits that are independent of dopaminergic medication.
Velocity of checking boxes was the only parameter of this 
study that significantly improved by dopaminergic medication 
during both ST and DT. This finding suggests that cognitive tasks 
with a substantial fine motor aspect, performed with the upper 
limbs, are stably responsive to dopaminergic medication, regard-
less whether the task is performed alone or in parallel to other 
tasks. This finding fits well with the high correlation of the Purdue 
pegboard test scores with the nigrostriatal dopaminergic deficit 
as measured with fluorodopa positron emission tomography 
(Vingerhoets et al., 1997), and with the clinical observation that 
rigidity and bradykinesia of the upper limbs present with very 
good responsiveness to dopaminergic treatment.
The study faces some limitations. First, the number of (especially 
female) participants included in this study is relatively low, and 
results should therefore be interpreted with caution. However, we 
did not find relevant differences between male and female perfor-
mance in a post hoc analysis (not shown). Second, our study focused 
on the assessment of PD patients with relatively early disease stages. 
Future studies should also include more severely affected patients, 
to allow generalization of our findings. Finally, due to technical 
issues, the performance of cognitive tasks was recorded over all gait 
phases and not separately for straight walking and turning phases. 
We argue that the results are still ecologically valid, as secondary 
tasks are routinely performed during walking, e.g., in the home, 
where straight walking and turning phases regularly alternate.
In conclusion, dopaminergic medication is obviously not 
relevantly beneficial for mild-to-moderate PD patients during 
straight walking and turning under DT conditions, which we 
consider the more daily relevant condition than the usually tested 
ST condition.
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